OncoMatch/Clinical Trials/NCT07301866
A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.
Is NCT07301866 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies ECT-001-CB for acute leukemia, high risk.
Treatment: ECT-001-CB — This clinical study is testing a new way to improve stem cell transplants for adults with high-risk blood cancers, such as leukemia or myelodysplasia, who do not have a suitable donor. The transplant uses stem cells from umbilical cord blood that have been expanded in the lab using a molecule called UM171. Previous studies showed that UM171 helps these cells grow and work better, leading to faster blood count recovery and fewer complications. In this study, researchers are testing whether increasing the dose of UM171 during the lab expansion process can make the transplant less toxic. The hypothesis is that using a higher dose of UM171 to expand cord blood stem cells will help patients recover blood counts faster after transplant by improving the growth and function of the cells. This may lead to better immune recovery, fewer infections, shorter hospital stays, and improved overall outcomes. Only seven patients will be enrolled, and they will be followed for one year after their transplant.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Non-Hodgkin Lymphoma
Multiple Myeloma
Chronic Lymphocytic Leukemia
Prior therapy
Cannot have received: allogeneic or autologous myeloablative transplant
Lab requirements
Kidney function
Estimated or measured creatinine clearance ≥ 60 ml/min/1.73m2
Liver function
Bilirubin < 2 x ULN unless felt to be related to Gilbert's disease or hemolysis; AST and ALT ≤ 2.5 x ULN (PI may approve up to 3 times ULN); alkaline phosphatase ≤ 5 x ULN
Cardiac function
Left ventricular ejection fraction ≥ 40% within 60 days prior to start of conditioning regimen
Adequate cardiac function: Left ventricular ejection fraction ≥ 40% within 60 days prior to start of conditioning regimen; Adequate pulmonary function: FVC, FEV1 and DLCOc ≥ 50% of predicted within 60 days prior to start of conditioning regimen; Adequate hepatic function: Bilirubin < 2 x ULN unless felt to be related to Gilbert's disease or hemolysis; AST and ALT ≤ 2.5 x ULN (PI may approve up to 3 times ULN); alkaline phosphatase ≤ 5 x ULN; Adequate renal function: Estimated or measured creatinine clearance ≥ 60 ml/min/1.73m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify